

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31824CID2	PRED. SERIAL NO. 19068-514 10/7/6 923
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Granett, et al.	
		PRED. FILING DATE February 5, 2002	PRED. GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
↓	5,972,944	10/1999	Antonucci, et al.	514	252	
	5,002,953	3/26/91	Hindley			
	5,194,443	3/16/93	Hindley			
	5,232,925	8/3/93	Hindley			
	5,260,445	11/9/93	Hindley			
	5,521,201	5/28/96	Hindley, et al.			
	5,646,169	7/8/97	Hindley, et al.			
	5,741,803	4/21/98	Pool, et al.			
	5,756,525	5/26/98	Hindley, et al.			
	5,910,592	6/8/99	Pool, et al.			
	6,288,095	9/11/01	Hindley, et al.			
	6,166,049	12/26/00	S.A. Smith			
↓	US20020049240	4/25/02	Hindley, et al.			

FOREIGN PATENT DOCUMENTS



	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
↓	WO 98/02159	1/22/98	PCT				
	WO 95/21608	8/17/95	PCT				
	WO 97/05875	2/20/97	PCT				
	WO 97/18811	5/29/97	PCT				
	WO 94/05659	3/17/94	PCT				
	0 796 618 A	9/24/97	EP				
	0 306 228 A	3/8/89	EP				
	0 419 035 A1	3/27/91	EP				
	0 419 035 B1	2/15/95	EP				
	WO 94/25026	11/10/94	PCT				
	WO 95/07694	3/23/95	PCT				
	WO 97/25042	7/17/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

↓	"R&D Focus Drug News", Dialog File Supplier: File 445 R&D Focus, Accession Nos. 16402 and 14818, 05 May 1997 - 10 March 1997, XP002082979.	DATE CONSIDERED 3/20/04
	"Rosiglitazone SmithKline Beecham Clinical Data", STN File Supplier: Drugnl: Accession Number 1391 & R&D Focus Drug News, 17 April 1998, XP002082989.	
	"The Pink Sheet", Dialog File Supplier: File 187: F-D-C Reports; Accession Number 600160005, 60(16): 20 April 1998, XP002082978.	
↓	Berger, et al., "Thiazolidinediones Produce a Conformational Change in Peroxisomal Proliferator-Activated Receptor-γ: Binding and Activation Correlate with Antidiabetic Actions in db/db Mice". <i>Endocrinology</i> , 137(10): 4189-4195 (1996). XP000613643.	
EXAMINER		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31824C1D2	PRED. SERIAL NO. 10/068,514 10/7/02 923
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Granett, et al.	
		PRED. FILING DATE February 5, 2002	PRED. GROUP ART UNIT 1614



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US20030149054	8/7/03	Hindley et al. - Corresponds to previously cited U.S. Patent Appln. No. 10/071,824 (Docket No.: B2368).			
	US20030109552	6/12/03	Buckingham - Corresponds to previously cited U.S. Patent Appln. No. 09/989,798 (Docket No.: P30879).			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Chapter 89, pp. 1583-1586.
	Physician's Desk Reference, 54th Edition, 2000, Medical Economics Company, pp. 2980-2984, Citation based on product labeling dated June 15, 1999.
EXAMINER	DATE CONSIDERED 3/20/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. n:\kls\cases\p31824c1d2\prior art pto 1449 form.doc	